bronchospasm
Respiratory · 2019–2020
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| terbutaline Reliever inhaler for the management of bronchospasm in patients unable to use a pressurised metered-dose inhaler or who have experienced adverse effects with… | Jul 2020 | Recommended | input received Lung Foundation Australia |
| terbutaline Reliever therapy for bronchospasm in patients unable to use pressurised metered dose inhalers or who develop adverse effects with alternative short-acting… | Jul 2019 | Recommended with restriction | no section in document |
Who spoke
Lung Foundation Australia
What the PBS pays
$1M in government benefit over 2024–25, across 47,841 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| terbutaline | $1.1M |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| ephedrineDBL EPHEDRINE SULFATE 30mg/1mL Injection | 1991 | 8 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.